8 completed, 5 terminated, 1 active not recruiting, 1 recruiting. 17 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 8, Terminated 5, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow sonidegib: new trials by email Literature Review of sonidegib trials Research Report on sonidegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma Irinotecan, Sonidegib, Sorafenib - Hepatocellular Carcinoma | Phase 2 | Recruiting | University of Florida | 12 | 2024-12-02 | 2026-07-14 |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma Sonidegib, Cisplatin, Lomustine - Medulloblastoma | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 20 | 2022-11-11 | 2025-10-23 |
| Anti-PD1-antibody and Pulsed HHI for Advanced BCC Cemiplimab Injection [Libtayo] - Basal Cell Carcinoma | Phase 2 | Unknown | Reinhard Dummer | 20 | 2021-02-18 | 2024-07-30 |
| Tailored Sonidegib Schedule After Complete Response in BCC Sonidegib - Locally Advanced Basal Cell Carcinoma | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 21 | 2021-01-12 | 2026-06-01 |
| A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma Sonidegib, Imiquimod, Surgery - Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified | Phase 2 | Completed | Melanoma Institute Australia | 16 | 2019-07-23 | 2025-12-16 |
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer | Phase 2 | Terminated | Anne Chang | 10 | 2015-02-01 | 2019-01-29 |
| Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma LDE225, Bortezomib - Multiple Myeloma | Phase 2 | Terminated | SCRI Development Innovations, LLC | 7 | 2015-01-01 | 2017-02-16 |
| LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Erismodegib, Placebo - Breast Neoplasms | Phase 2 | Withdrawn | Washington University School of Medicine | 2014-04-01 | 2015-04-27 | |
| LDE225 for Patients With PTCH1 or SMO Mutated Tumors LDE225 - PTCH1 or SMO Activated Solid and Hematologic Tumors | Phase 2 | Terminated | Novartis Pharmaceuticals | 10 | 2014-02-01 | 2016-05-02 |
| Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Laboratory Biomarker Analysis, Lenalidomide, Sonidegib - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 28 | 2014-01-17 | 2021-12-03 |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF LDE225, INC424 - Primary Myelofibrosis, Thrombocytosis | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 50 | 2013-05-08 | 2020-04-15 |
| A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) LDE225, TMZ - Medulloblastoma | Phase 2 | Completed | Novartis Pharmaceuticals | 22 | 2013-05-06 | 2017-08-11 |
| Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia LDE225 - Acute Leukemias | Phase 2 | Completed | Novartis Pharmaceuticals | 70 | 2013-05-01 | 2016-08-30 |
| Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma LDE225-600mg, Gemcitabine, nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 23 | 2011-12-27 | 2020-01-22 |
| A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma LDE225 - Basal Cell Carcinoma | Phase 2 | Completed | Novartis Pharmaceuticals | 230 | 2011-06-29 | 2019-08-28 |
| Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) LDE225, Placebo - Basal Cell Carcinoma, Gorlin Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 10 | 2011-04-01 | 2015-10-19 |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB LDE225 - Medulloblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 76 | 2011-02-01 | 2017-03-20 |
Carcinoma, Basal Cell (5) · Basal Cell Nevus Syndrome (3) · Medulloblastoma (3) · Recurrence (3) · Skin Neoplasms (3) · Multiple Myeloma (2) · Astrocytoma (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1)
Novartis Pharmaceuticals (7) · Anne Chang (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Gruppo Oncologico del Nord-Ovest (1) · Mayo Clinic (1) · Melanoma Institute Australia (1) · Reinhard Dummer (1) · SCRI Development Innovations, LLC (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Florida (1) · Washington University School of Medicine (1)
United States (10) · Australia (7) · Canada (6) · Germany (6) · Italy (6) · France (5) · Spain (5) · United Kingdom (5) · Belgium (4) · Netherlands (4) · Switzerland (4) · Austria (3) · Hungary (2) · Brazil (1) · Denmark (1)
Ali Zarrinpar, MD, PhD (1) · Ana De Jesus-Acosta, MD (1) · Anne Lynn Chang, MD (1) · Cynthia Ma, M.D., Ph.D. (1) · Francis Buadi (1) · Jesus G. Berdeja, M.D. (1) · Paolo Bossi, MD (1) · Pascale Guitera, MD PhD (1) · Peter Hau (1) · Rebecca Aft, M.D., Ph.D. (1) · Reinhard Dummer, Prof. (1)
PMID 25981810, PMID 28846163, PMID 29175429, PMID 32634234, PMID 34669179, PMID 34798846
P30CA015083 (1)